BioCardia received a formal notice from Nasdaq on April 10, 2026, regarding non-compliance with listing rules. The company's stockholders' equity was reported at $895,000 as of December 31, 2025, falling below the $2.5 million minimum threshold. The company has until May 25, 2026, to submit a compliance plan to Nasdaq. Trading of BCDA common stock remains unaffected at this time.